USPTO serial 97405280
ADPL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Sep 5, 2023
- Examiner
- CLONCH, ABIGAIL
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ADPL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Meghna Prasad
Meghna Prasad BAKER BOTTS L.L.P.44TH FLOOR30 ROCKEFELLER PLAZANEW YORK, NY 10112-4498Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines, and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Mercury Pharma Group Limited
- Other trademarks owned by Mercury Pharma Group Limited
- Other trademarks owned by Mercury Pharma Group Limited
- Other trademarks in Class 005
- Similar marks named ADPL
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 5, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Sep 5, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 20, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 20, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 31, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 15, 2023 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 8, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 4, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 4, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 4, 2023 | ALIE | ASSIGNED TO LIE | — |
| Feb 2, 2023 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jan 24, 2023 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 24, 2023 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 24, 2023 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jan 24, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 24, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 24, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 24, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 18, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| May 17, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 14, 2022 | NWAP | NEW APPLICATION ENTERED | — |